All times are Eastern Standard Time.

Thursday, February 9

11:00 AM  Online Expo

11:30 AM  APC State of the Association – Board Chair Anthony Grzib, RPh, Wedgewood Pharmacy; Immediate Past Board Chair David J. Miller, RPh, PhD, FAPC, FACA, Keystone Pharmacy; and CEO Scott Brunner

12:00 PM  The Compounders' Code of Ethics & Your Commitment to Quality – AJ Day, PharmD; PCCA
What steps are you taking to ensure your patients have positive outcomes today and tomorrow? How does that impact your reputation, and the reputation of our industry? Join us for a discussion on The Compounder’s Code of Ethics and quality systems you are building to ensure a bright future.

1:00 PM  Concurrent Sessions:
- **Ask the Testing Lab: Common Questions from Compounders – Dr. Wayne DeHaven, Pharmetric Laboratory**
The new versions of USP <795> and <797> will become official on November 1st 2023. Compounding pharmacies and laboratories alike are busy preparing for the many updates to the chapters. Details are now included in the chapters which explain the basics required for establishing and extending the Beyond Use Dates (BUDs) of Compounded Sterile and Non-Sterile Products (CSPs and CNSPs). The extension of BUDs requires published literature and laboratory testing to ensure the safety and efficacy of the products through the BUD. The most common questions Pharmetric Lab receives are associated with these tests in support of the extension of BUDs. The presentation will provide details of several microbiological, biological, and analytical tests utilized in extending BUDs within the framework of the new <795> and <797>. Case studies will be provided to highlight the outcomes which can occur when the CSP/CNSP does not meet the expected outcomes.
- **How to Conduct a Gap Analysis – Melissa Stefko, Senior Director of Quality, The FlexPro Group**
This talk will map out an effective gap analysis audit plan from audit strategy development through execution and remediation with input from SMEs.

2:00 PM  Patron Showcase: PCCA
2:15 PM  **Common Mistakes, Uncommon Consequences (And How to Avoid ‘Em) – L. Rad Dillon, RPh, ACHC**
A long-time accreditation surveyor has observed over the years many "sins of omission" and "of commission" - that is, practices that are either being done incorrectly, or not performed at all. He has also gathered input from a number of peers and colleagues. This presentation will provide all compounders with some valuable ways to improve the efficiency, safety, and effectiveness of their practice.

3:15 PM  Patron Showcase Fagron

3:30 PM  **Cleaning and Organizing is a Practice, Not a Project: Tools to Avoid Insanitary Conditions in Your Pharmacy – Matt Martin, PharmD, BCSCP, Director of Clinical Services, PCCA**
Much of FDA’s inspection activity in compounding facilities has been focused on what they consider insanitary conditions. In this presentation we will review inspection findings and talk about strategies to avoid these from existing in your practice.

4:30 PM  **Best Practices for Assigning BUDs Under the New USP Chapters – Melissa Stefko, Senior Director of Quality, The FlexPro Group**
This talk will dissect the new language in the USP 795 and 797 and how it is applied to setting beyond use dates. We will also discuss how to prepare your operations for the changes and how existing stability studies are affected.

5:30 PM  **Healthier Patients = Healthier Practice – TW Taylor, RPh, Williamsburg Drug Company**
Are you helping your patients be their healthiest? Meeting the client where they are can increase their health in measurable ways. This session will look at ways to show your patients "How the time, money and effort spent are making you are healthier!"

**Friday, February 10**

11:00 AM  Online Expo

11:30 AM  Pharmacy Compounding Foundation and Pharmacists Mutual Insurance Company Scholarship Award

11:45 AM  Patron Showcase: Medisca

12:00 PM  **Compounding for Thyroid the Right Way! – Michelle Moser, RPh, FACA, FAVCP, FAPC; Makers Compounding Pharmacy**
Compounding Levothyroxine, Liothyronine & Thyroid USP is more than packing capsules. Ensuring accuracy, dosage & potency is key to providing a safe & beneficial compounded hormone product. We will talk about reading the CofA, making a triturate, the math involved, as well as should you make a long-acting or immediate release product and why!
1:00 PM  **Latest/Greatest Trends in Dermatological Compounding – Dr. Raja Sivamani, MD, MS**
This presentation will review the basics of compounding within dermatology. The lecture will overview base options when considering dermatology focused compounding and will review popular ingredients that are utilized in the areas of hair loss and acne. As there are more antioxidants available on the market, the use of antioxidants will be reviewed as well.

2:00 PM  **Latest/Greatest Trends in Women’s Health Compounding – Dr. Pamela W. Smith, MD, MPH, MS**
The science behind women’s hormones, their function and replacement, has been extensively studied over the years. This seminar will be conducted by Dr. Pamela W. Smith, M.D., MPH, MS who is an internationally known physician, author, and educator. It will examine the biochemistry and physiology of women’s hormones, factors that influence each step, along with reasons to consider hormone replacement therapy as the standard of care for all women.

3:00 PM  **Latest/Greatest Trends in Geriatrics & Hospice Compounding – Mindy Cormier, RPh, PharmD, Medisca**
As the global patient demographic changes with the rapid increase in geriatric patients, so does the need to change and adjust healthcare treatments and goals in order to optimally manage associated diseases and to improve quality of life. This activity will discuss the growing market for compounding sterile and non-sterile preparations for the geriatric and hospice population, as well as to discuss compounded treatments covering a variety of disease states specific to this growing demand in healthcare.

4:00 PM  **And Now a Word from Legal Counsel... – Martha M. Rumore, PharmD, JD, LLM, FAPhA, Frier Levitt LLC**
Beta lactams? Semaglutide compounding? Insanitary conditions? Animal compounding? This session will address law and regulations pertaining to compounders, including the current state of the Federal Food, Drug and Cosmetic Act Section 503A on compounding shortage medications and substances such as peptides, DTE and bHRT therapies. Implementation of revised USP guidelines for sterile and non-sterile drug products, as well as the future of interstate distribution of compounded drug products, will be discussed.